It has been known for some time that approximately 98% of ALS patients share TDP-43 mislocalization (22) and new research linking this change to molecular and clinical phenotypes suggests that this may represent a final common pathway of ALS amenable to therapeutic intervention (23–25). The gene discussed is TARDBP; the disease is amyotrophic lateral sclerosis.